SciClone Pharmaceuticals IPO Initiation: A Hard Sell
SciClone is pre-marketing a Hong Kong IPO to raise $500 million, according to press reports. Overall, on a fundamental basis, we are inclined to...
491 Views
SciClone Pharmaceuticals: Caged by the Elephant
SciClone Pharmaceuticals is a China-based company that has filed to list on the HKEX. We expect concerns about VBP for Zadaxin to weigh on the...
314 Views
Pre-IPO SciClone Pharmaceuticals - Here Are the Strength and the Concerns
This article analyzed SciClone Pharmaceuticals in terms of its core product Zadaxin, products in the pipeline, financial position and also include...
314 Views
ECM Weekly (7 February 2021) - Kuaishou, New Horizon, SciClone, Cloopen
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
366 Views
SciClone Pharma (赛生药业) Pre-IPO: PHIP Updates and Thoughts on Valuation
In this note, we forecast the company's revenue and net profit. We also value the company with reference to peer pharmaceutical companies listed in...
476 Views